Check out this recent article to learn how CKB can be your genomic digital encyclopedia of cancer!
Mainstreaming Precision Oncology
The JAX-CKB team is looking for a
Variant Assay Interpretation Scientist! More details regarding this exciting position can be found here.
CKB CORE now offers content for RSPO3, POLE, FANCA, and DOT1L, but removes EGFR, PTEN, TP53, and MET. However, these genes are always accessible with a
CKB BOOST subscription!
We're looking for new people to join the JAX-CKB team! Check out the job listings here:
Scientific Software Engineer
Have a question about CKB or want to learn more about it? Then check out
The Scoop on CKB!
BOOST now has AMP/CAP/ASCO evidence level coding!
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit
ckbhome.jax.org and sign-up for CKB BOOST.
Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at